Common use of INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE Clause in Contracts

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018, including any amendments or reports filed for the purpose of updating such description. You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS Jefferies

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to “incorporate by reference much of the reference” information from other documents that we file with the SECit, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate incorporated by reference in this prospectus is considered to be part of this prospectusprospectus supplement. Because we are incorporating Information in this prospectus supplement supersedes information incorporated by reference future filings that we filed with the SEC prior to the date of this prospectus supplement. We incorporate by reference into this prospectus supplement and the registration statement of which this prospectus supplement is a part the following documents that we have filed with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • ● our Annual Report on Form 10-K for the fiscal year ended December 31, 20182019 filed on March 12, including the information specifically incorporated by reference into the Annual Report on Form 10-K from 2020; ● our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 20192020 filed on May 14, 2020; • ● our Definitive Proxy Statement on Schedule 14A filed on April 29, 2020; ● our Current Reports on Form 8-K filed on January 3March 30, 20192020 and May 13, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively2020; and • The ● the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on June 22December 13, 20182017, including any amendments or reports filed for the purpose of updating such description. We also incorporate by reference all documents that we file with the SEC on or after the date of this prospectus pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act and prior to the sale of all the securities registered hereunder or the termination of the registration statement. Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC. Any statement contained in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference in this prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus supplement, the accompanying prospectus to the extent that a statement contained herein or in the applicable prospectus supplement or in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes the statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. You may request a copy of these filingsthe filings incorporated herein by reference, including exhibits to such documents that are specifically incorporated by reference, at no cost, by writing or telephoning calling us at the following address or telephone number: Translate BioCorporate Secretary Chief Executive Officer 0000 Xxxxx Xx., Suite 2050 Menlo Park, CA 94025 (650) 446-7888 Statements contained in this prospectus supplement as to the contents of any contract or other documents are not necessarily complete, and in each instance you are referred to the copy of the contract or other document filed as an exhibit to the registration statement or incorporated herein, each such statement being qualified in all respects by such reference and the exhibits and schedules thereto. WHERE YOU CAN FIND MORE INFORMATION This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the SEC registering the securities that may be offered and sold hereunder. The registration statement, including exhibits thereto, contains additional relevant information about us and these securities that, as permitted by the rules and regulations of the SEC, we have not included in this prospectus supplement or the accompanying prospectus. A copy of the registration statement can be obtained at the address set forth below or at the SEC’s website as noted below. You should read the registration statement, including any applicable prospectus supplement, for further information about us and these securities. We file annual reports, quarterly reports, current reports, proxy statements and other information with the SEC under the Securities Exchange Act of 1934, as amended. The SEC maintains an Internet website at xxxx://xxx.xxx.xxx where you can access copies of most of our SEC filings. We make our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, available free of charge on our corporate website at xxx.xxxxxx.xxx. The contents of our corporate website are not incorporated into, or otherwise to be regarded as part of, this prospectus supplement. PROSPECTUS COHBAR, INC. $100,000,000 Common Stock Preferred Stock Warrants Units We may offer from time to time shares of our common stock, par value $0.001 (“Common Stock”), preferred stock, warrants, and units that include any of these securities. The aggregate initial offering price of the securities sold under this prospectus will not exceed $100,000,000. We will offer the securities in amounts, at prices and on terms to be determined at the time of the offering. Shares of our common stock are quoted on the TSX Venture Exchange (TSX-V) under the symbol “COB.U” and on the OTCQX marketplace operated by OTC Markets Group, Inc. Attention: Xxxx Xxxxxxxunder the symbol “CWBR.” On November 21, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington2017, Massachusetts 02421 the closing prices for our common stock on the TSX-V and OTCQX were $4.80 and $4.75 per share, respectively. Each time we sell securities hereunder, we will attach a supplement to this prospectus that contains specific information about the terms of the offering, including the price at which we are offering the securities to the public. The prospectus supplement may also add, update or change information contained or incorporated in this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you invest in our securities. The securities hereunder may be offered directly by us, through agents designated from time to time by us or to or through underwriters or dealers. If any agents, dealers or underwriters are involved in the sale of any securities, their names, and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the section entitled “About This Prospectus” for more information. Investing in our securities involves certain risks. See “Risk Factors” beginning on page 5 of this prospectus. In addition, see “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, which has been filed with the Securities and Exchange Commission and is incorporated by reference into this prospectus. You should carefully read and consider these risk factors before you invest in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus is December 1, 2017. TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 THE COMPANY 1 RISK FACTORS 5 FORWARD-LOOKING STATEMENTS 5 USE OF PROCEEDS 6 DESCRIPTION OF CAPITAL STOCK 6 DESCRIPTION OF COMMON STOCK 6 DESCRIPTION OF PREFERRED STOCK 7 DESCRIPTION OF WARRANTS 8 DESCRIPTION OF UNITS 9 PLAN OF DISTRIBUTION 9 LEGAL MATTERS 10 EXPERTS 10 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 11 WHERE YOU CAN FIND MORE INFORMATION 11 The distribution of this prospectus may be restricted by law in certain jurisdictions. You should inform yourself about and observe any of these restrictions. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this document are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this prospectus does not extend to you. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of the offering and the offered securities. This prospectus, together with applicable prospectus supplements, any information incorporated by reference, and any related free writing prospectuses we file with the Securities and Exchange Commission (000) 000-0000 20 Up the “SEC”), includes all material information relating to $50,000,000 Common Stock PROSPECTUS Jefferiesthese offerings and securities. We may also add, update or change in the prospectus supplement any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus, including without limitation, a discussion of any risk factors or other special considerations that apply to these offerings or securities or the specific plan of distribution. We have not authorized anyone to give any information or make any representation about us that is different from, or in addition to, that contained in this prospectus, including in any of the materials that we have incorporated by reference into this prospectus, any accompanying prospectus supplement, and any free writing prospectus prepared or authorized by us. Therefore, if anyone does give you information of this sort, you should not rely on it as authorized by us. You should rely only on the information contained or incorporated by reference in this prospectus and any accompanying prospectus supplement. You should not assume that the information contained in this prospectus and any accompanying supplement to this prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying supplement to this prospectus is delivered or securities are sold on a later date. Neither the delivery of this prospectus, nor any sale made hereunder, shall under any circumstances create any implication that there has been no change in our affairs since the date hereof or that the information incorporated by reference herein is correct as of any time subsequent to the date of such information.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us This consent solicitation statement incorporates by reference the documents listed below that we have previously filed with the Securities and Exchange Commission and that are not included in or delivered with this document. They contain important information about our company and its financial condition. FILING PERIOD Annual Report on Form 10-K Year ended September 30, 1999 Quarterly Reports on Form 10-Q Quarter ended December 31, 2000 Quarter ended March 31, 2000 Current Report on Form 8-K Filed March 17, 2000 Pages two through eleven, "Election Filed December 10, 2000 of Directors", through Executive Compensation-Compensation Committee Interlocks and Insider Participation" and page sixteen, "Section 16(a) Beneficial Ownership Reporting Compliance," contained in our Proxy Statement dated December 10, 1999, relating to our 2000 annual meeting of stockholders and incorporated into our Annual Report on Form 10-K We also incorporate by reference much of the information additional documents that we may file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documentsSEC between the date of this consent solicitation statement and the date the proposed amendment becomes effective. The information that we incorporate incorporated by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating consent solicitation statement, except for any information that is superseded by reference future filings with the SEC, this prospectus information that is continually updated and those future filings may modify or supersede some of the information included or incorporated directly in this prospectusdocument. This means that you must look at all of the SEC filings that we incorporate by reference to determine if You can obtain any of the statements in this prospectus or in any document previously documents incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and in this document from us without charge, excluding any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than exhibits to those documents or unless the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement exhibit is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018, including any amendments or reports filed for the purpose of updating such descriptionas an exhibit to this consent solicitation statement. You may request a copy of these filings, at no cost, can obtain documents incorporated by reference in this consent solicitation statement by requesting them in writing or telephoning by telephone from us at the following address or telephone numberaddress: Translate BioAssistant to Corporate Counsel X.X. Xxxxxx, Inc. Attention: Xxxx Xxxxxxx0000 Xxxxxxxxx Xxxxxxxxx Xxxxx 000 Xxxxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 Xxxxx 00000 (000) 000-0000 20 Up 0000, ext. 1046 THE PROPOSED AMENDMENT We issued $150,000,000 aggregate principal amount of our 10-1/2% senior notes on March 21, 2000. We seek the proposed amendment in order to issue in the near future up to an additional $50,000,000 aggregate principal amount of our 10-1/2% senior notes. The indenture currently limits the principal amount of these notes to $150,000,000. The proposed amendment would increase this limit by $50,000,000 if we are successful in issuing any additional notes. If we are not successful in issuing any additional notes and we so advise the trustee, the limit would remain at $150,000,000. If the limit is increased but we do not issue all of the additional notes, the indenture would permit us to issue the balance of the additional notes in the future. We would use the net proceeds of the issuance of any additional notes to pay down outstanding borrowings under our existing revolving credit facility, which will increase availability under our revolving credit facility, and for general corporate purposes. Any issuance of the additional notes will comply with the debt incurrence tests contained in the indenture and would comprise part of the same series of securities as the outstanding 10-1/2% senior notes. CAPITALIZATION The following table sets forth our capitalization at March 31, 2000, as adjusted to reflect the issuance of an additional $50,000,000 aggregate principal amount of notes and the application of the estimated net proceeds of the issuance. As of March 31, 2000 Actual Adjusted(1) ($ in thousands) ---------------------------- Homebuilding debt: Notes payable under revolving credit facility(2) $500,000 $450,880 Notes payable"other 8,617 8,617 8 3/8% senior notes due 2004, net 148,348 148,348 10 1/2% senior notes due 2005, net 149,415 199,415 10% senior notes due 2006, net 147,338 147,338 8% senior notes due 2009, net 383,014 383,014 ------- ------- Total homebuilding debt 1,336,732 1,337,462 Notes payable under mortgage warehouse facility 76,800 76,800 ------ ------ Total debt 1,413,532 1,414,262 --------- --------- Stockholders' equity: Preferred stock, $.10 par value; 30,000,000 shares authorized, no shares issued -- -- Common Stock PROSPECTUS Jefferiesstock, $.01 par value; 200,000,000 shares authorized, 64,396,305 shares, issued and outstanding 644 644 Additional capital 420,643 420,643 Retained earnings 477,737 477,737 Treasury stock (36,947) (36,947) -------- -------- Total stockholders' equity 862,077 862,077 ------- ------- Total capitalization $2,275,609 $2,276,239 ========== ========== ----------- (1) Adjusted to reflect the sale of $50,000,000 of additional notes and the application of the estimated net proceeds to repay debt under our revolving credit facility.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows SEC’s rules allow us to “incorporate by reference much of the reference” information we file with the SECinto this prospectus, which means that we can disclose important information to you by referring you to those publicly available documentsanother document filed separately with the SEC. The information that we incorporate incorporated by reference in this prospectus is considered deemed to be part of this prospectusprospectus from the date of filing those documents. Because we are incorporating Any reports filed by us with the SEC on or after the date of this prospectus will automatically update and, where applicable, supersede any information contained in this prospectus or incorporated by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference We have been modified or superseded. This prospectus incorporates by reference filed the documents listed below (File No. 001-38550) and any future filings we make with the SEC under the Exchange Act, and these documents are incorporated herein by reference (other than information in such documents that is furnished and not deemed to be filed): · Our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended by that Form10-K/A, filed with the SEC on April 28, 2021; · Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021; · Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 12, 2021; · Our Current Reports on Form 8-K filed with the SEC onJuly 16, 2021, July 28, 2021, and October 15, 2021; and · The description of our Common Stock included in our Registration Statement on Form8-A, filed on November 1, 2016. All documents we subsequently file pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of the securities to which this prospectus relates (in each case, other than those information in such documents or the portions of those documents that is furnished and not deemed to be filed) between shall be deemed to be incorporated by reference into this prospectus and to be a part hereof from the date of filing of those documents. All documents we file pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement that contains this prospectus and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and following to be a part hereof from the effectiveness date of filing those documents. We will provide to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of any or all of the registration statement until information that has been incorporated by reference in this prospectus but not delivered with this prospectus (other than the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information exhibits to such documents which are not specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholderstherein); • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018, including any amendments or reports filed for the purpose of updating such description. You may request a copy of these filings, we will provide this information at no costcost to the requester upon written or oral request to: Corporate Secretary at Xenetic Biosciences, by writing Inc., 00 Xxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxxx, Xxxxxxxxxxxxx 00000, or telephoning us at the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 0000. 30 XENETIC BIOSCIENCES, INC. Up to $50,000,000 4,000,000 of shares of Common Stock PROSPECTUS JefferiesSUPPLEMENT NOVEMBER 19, 2021

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and 38134)and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 20182019, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 2020 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 20192020; • Current Reports on Form 8-K filed on January 7, 2020, February 18, 2020, March 19, 2020 and April 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 20192020, respectively, and Current Reports Report on Form 8-K/A filed with the SEC on June 19February 26, 2019 and June 19, 2019, respectively2020; and • The description of our Class A common stock contained in our Registration Statement on Form 8-A filed on June 2226, 20182017, including any amendments or reports filed for the purpose of updating such description. You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Translate BioBlue Apron Holdings, Inc. AttentionAttn: Xxxx XxxxxxxGeneral Counsel 00 Xxxxxxx Xxxxxx New York, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 New York 10005 Telephone: (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS Jefferies0000

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. We file or furnish annual and current reports and other information with the SEC (File Number 001-36187). These filings and other submissions contain important information that does not appear in this prospectus. The SEC allows us to “incorporate by reference much of the reference” information we file with the SECin this prospectus, which means that we can disclose important information to you by referring you to those publicly available documents. The information other documents that we incorporate have filed or furnished, or will file or furnish, with or to the SEC and such information incorporated by reference in this prospectus is then considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we We incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings all amendments or supplements to such documents that we make with may file or furnish to the SEC under Sections pursuant to Section 13(a), 13(c), 14 ) or 15(d) of the Exchange Act Act: • Our 2019 annual report; • The description of our ordinary shares contained in Form 8-A, File No. 001-36187, filed with the SEC on December 29, 2016, as amended by Exhibit 2.1 to our 2019 annual report; and • Our Reports of Foreign Private Issuer on Form 6-K furnished to the SEC on May 6, 2020, May 26, 2020 (relating solely to the consolidated statements of financial position tables for the quarter ended March 31, 2020 contained in the press release attached as exhibit 99.1 thereto) and May 28, 2020. We furthermore incorporate by reference in this prospectus each caseof the following documents, other than those documents which will be considered a part of this prospectus from the date of filing or furnishing of such documents: • any Reports of Foreign Private Issuer on Form 6-K furnished to the portions of those documents not deemed to be filed) between SEC by us after the date of the initial registration statement and of which this prospectus forms a part that we specifically identify in such reports as being incorporated by reference in that registration statement; • all subsequent Annual Reports on Form 20-F filed after the effectiveness effective date of the registration statement of which this prospectus forms a part and following prior to the effectiveness termination of this offering; and • any Reports of Foreign Private Issuer on Form 6-K subsequently furnished to the SEC after the effective date of the registration statement until of which this prospectus forms a part, or portions thereof, that we specifically identify in such reports as being incorporated by reference in that registration statement. Certain statements in and portions of this prospectus update and replace information in the offering above-listed, already-filed or furnished documents incorporated by reference. Likewise, statements in or portions of a future document listed above that is incorporated by reference in this prospectus may update and replace statements in and portions of this prospectus or the above-listed documents. We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge, upon written or oral request, a copy of any or all of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31information that has been incorporated by reference in this prospectus, 2018, including the information other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to our headquarters, which are currently located at 00 Xxx Xxxxxxxxx Street, Park Rehovot, Rehovot P.O.B 0000, Xxxx Xxxxx, 7414002, Israel, Attn: VP Legal Affairs & Company Secretary, telephone number: +000-0-0000-000. Copies of these filings and submissions may also be accessed at our website, xxxxx://xxx.xxxxxxx.xxx/. Information contained in our website is not part of this prospectus. ENFORCEABILITY OF CIVIL LIABILITIES We are incorporated under the Annual Report laws of the State of Israel. Service of process upon us and upon certain of our directors and officers and the Israeli experts named in this prospectus whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because a significant portion of our assets and substantially all of our directors and officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may be difficult to collect within the United States. It may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on Form 10a violation of U.S. securities laws based on the reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-K from our definitive proxy statement for consuming and costly process. Certain matters of procedure will also be governed by Israeli law. Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the 2019 Annual Meeting civil liability provisions of Stockholdersthe Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that: • the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31prevailing law of the foreign state in which the judgments were rendered allows the enforcement of judgments of Israeli courts (however, 2019the Israeli courts may waive this requirement following a request by the attorney general); • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 adequate service of process has been affected and July 15, 2019, respectivelythe defendant has had a reasonable opportunity to be heard and to present his or her evidence; • the judgments are not contrary to public policy, and Current Reports on Form 8-K/A filed the enforcement of the civil liabilities set forth in the judgments does not impair the security or sovereignty of the State of Israel; • the judgments were not obtained by fraud and do not conflict with any other valid judgment in the SEC on June 19, 2019 and June 19, 2019, respectivelysame matter between the same parties; • an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and • The description the obligations under the judgment are enforceable according to the laws of the State of Israel and according to the law of the foreign state in which the relief was granted. We have irrevocably appointed Xxxxxxx & Associates as our common stock contained agent to receive service of process in our Registration Statement on Form 8any action against us in any United States federal or state court arising out of any offering, or any purchase or sale of securities in connection with any offering, under this prospectus. If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-A filed on June 22Israeli currency and transferred out of Israel. Under existing Israeli law, 2018, including any amendments or reports filed for the purpose of updating such description. You a foreign judgment payable in foreign currency may request a copy of these filings, at no cost, by writing or telephoning us be paid in Israeli currency at the following address rate of exchange in force on the date of the payment. Current Israeli exchange control regulations also permit a judgment debt or telephone number: Translate Bioto make payment in foreign currency. Pending collection, Inc. Attention: Xxxx Xxxxxxxthe amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS Jefferiesplus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference into this prospectus supplement and the accompanying prospectus much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in into this prospectus supplement and the accompanying prospectus is considered to be part of this prospectus supplement and the accompanying prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is supplement and the accompanying prospectus are continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus supplement and the accompanying prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement, the accompanying prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates supplement and the accompanying prospectus incorporate by reference the documents listed below (File No. 001-3855038134) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement ), until the offering of the securities under the registration statement is terminated or completed: . • Annual Report on Form 10-K for the fiscal year ended December 31, 20182021, including the information specifically incorporated by reference into the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 from our definitive proxy statement for the 2019 2022 Annual Meeting of Stockholders; ​ • Quarterly Report Reports on Form 10-Q for the fiscal quarter quarters ended March 31, 20192022, June 30, 2022 and September 30, 2022 (and with respect to the Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2022 and September 30, 2022, the additional disclosures relating to the Company’s ability to continue as a going concern in Note 2 to the Consolidated Financial Statements contained in such reports); ​ • Current Reports on Form 8-K filed on January February 10, 2022 (with respect to Item 8.01 and the portions of Item 9.01 described therein only), February 15, 2022, March 7, 2022, March 23, 2022, May 5, 2022, ​ TABLE OF CONTENTS May 10, 2022 (with respect to Item 8.01 and the portions of Item 9.01 described therein only), June 14, 2022, August 8, 2022 (with respect to Item 1.01 and the portions of Item 9.01 described therein only), September 6, 2022, September 7, 2022, September 26, 2022, October 3, 20192022, April November 7, 2022 (with respect to Item 1.01, Item 5.02 and the portions of Item 9.01 described therein only), November 14, 2022 (with respect to Item 1.01 and the portions of Item 9.01 described therein only), December 8, 20192022 (with respect to Item 8.01) and December 23, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed 2022 (with the SEC on June 19, 2019 and June 19, 2019, respectivelyrespect to Item 3.01 only); and • The description of our Class A common stock contained in our Registration Statement on Form 8-A filed on June 2226, 20182017, as amended by the description of our Class A common stock contained in Exhibit 4.2 to our Annual Report on Form 10-K for the year ended December 31, 2021 and including any amendments other amendment or reports filed for the purpose of updating such descriptiondescriptions. ​ You may request a copy of these filings, documents at no cost, by writing or telephoning calling us at the following address or telephone phone number: Translate BioBlue Apron Holdings, Inc. AttentionAttn: General Counsel 00 Xxxxxxx Xxxxxx Xxx Xxxx, Xxx Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 00000 Telephone: (000) 000-0000 20 Up TABLE OF CONTENTS PROSPECTUS $100,000,000 Debt Securities Class A Common Stock Preferred Stock Warrants We may offer and sell securities from time to time in one or more offerings of up to $50,000,000 Common 100,000,000 in aggregate offering price. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this prospectus and any applicable prospectus supplement before you invest. We may offer these securities in amounts, at prices and on terms determined at the time of offering. The securities may be sold directly to you, through agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement. Our Class A common stock is listed on the New York Stock Exchange under the symbol “APRN”. Investing in these securities involves certain risks. See “Risk Factors” on page 7 of this prospectus, included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities. We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision. ​ Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus is November 10, 2022 TABLE OF CONTENTS​ TABLE OF CONTENTS ​ ABOUT THIS PROSPECTUS Jefferies​ ​ ​ ​ 1 ​ ​ ​ WHERE YOU CAN FIND MORE INFORMATION ​ ​ ​ ​ 2 ​ ​ ​ INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE ​ ​ ​ ​ 2 ​ ​ ​ CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ​ ​ ​ ​ 4 ​ ​ ​ BLUE APRON HOLDINGS, INC. ​ ​ ​ ​ 6 ​ ​ ​ RISK FACTORS ​ ​ ​ ​ 7 ​ ​ ​ USE OF PROCEEDS ​ ​ ​ ​ 8 ​ ​ ​ DESCRIPTION OF DEBT SECURITIES ​ ​ ​ ​ 9 ​ ​ ​ DESCRIPTION OF CAPITAL STOCK ​ ​ ​ ​ 18 ​ ​ ​ DESCRIPTION OF WARRANTS ​ ​ ​ ​ 22 ​ ​ ​ FORMS OF SECURITIES ​ ​ ​ ​ 23 ​ ​ ​ PLAN OF DISTRIBUTION ​ ​ ​ ​ 25 ​ ​ ​ LEGAL MATTERS ​ ​ ​ ​ 27 ​ ​ ​ EXPERTS ​ ​ ​ ​ 27 ​ ​ TABLE OF CONTENTS​ ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”) utilizing a “shelf” registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate initial offering price of up to $100,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in the prospectus supplement. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading “Where You Can Find More Information” beginning on page 2 of this prospectus. You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. Unless the context otherwise indicates, references in this prospectus to “we,” “our” and “us” refer, collectively, to Blue Apron Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries. TABLE OF CONTENTS​​ WHERE YOU CAN FIND MORE INFORMATION We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at xxxx://xxx.xxx.xxx. Copies of certain documents filed by us with the SEC are also available on our website at xxxx://xxx.xxxxxxxxx.xxx. Our website is not a part of this prospectus and is not incorporated by reference into this prospectus. This prospectus is part of a registration statement that we filed with the SEC. The registration statement contains more information than this prospectus supplement and the accompanying prospectus regarding us and the securities, including certain exhibits and schedules. You can obtain a copy of the registration statement from the SEC’s internet site.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate documents listed below have been filed by reference much of the information we file Company under the Exchange Act with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we SEC and are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates into this prospectus: • The Company’s Annual Report on Form 10-K for the year ended December 31, 2019; • The information specifically incorporated by reference into the documents listed below (File No. 001Company’s Annual Report on Form 10-38550) and any future filings we make K for the year ended December 31,2019 from the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC under on March 23, 2020; • The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020; • The Company’s Current Reports on Form 8-K filed on January 6, 2020, March 24, 2020, March 30, 2020, April 1, 2020, April 2, 2020, April 22, 2020, and May 6, 2020; and • The description of the common stock in the Company’s registration statement on Form 8-A filed on March 18, 1994, including any amendments and reports filed for the purpose of updating such description. All documents that we file (but not those that we furnish) with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents on or after the portions date of those documents not this prospectus and prior to the termination of the offering of any securities covered by this prospectus and the accompanying prospectus supplement shall be deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into this prospectus and will automatically update and supersede the Annual Report on Form 10-K from our definitive proxy information in this prospectus, the accompanying prospectus supplement and any previously filed documents. This means that important information about us appears or will appear in these documents and will be regarded as appearing in this prospectus. To the extent that information appearing in a document filed later is inconsistent with prior information, the later statement for will control and the 2019 Annual Meeting prior information, except as modified or superseded, will no longer be a part of Stockholders; • Quarterly Report on Form 10-Q for this prospectus. Copies of all documents which are incorporated by reference into this prospectus and the fiscal quarter ended March 31applicable prospectus supplement (not including the exhibits to such information, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018unless such exhibits are specifically incorporated by reference) will be provided without charge to each person, including any amendments beneficial owner of the securities offered by this prospectus, to whom this prospectus or reports filed for the purpose of updating such descriptionapplicable prospectus supplement is delivered, upon written or oral request. Requests should be directed to our Secretary, 00 X. Xxxx Xxxx Xxxx, Xxxxxxxxxx Xxxxx, Xxxxxxxx 00000 (telephone number: (000) 000-0000). You may request a copy also obtain copies of these filings, at no cost, by accessing our website at xxx.xxxxxxxxxxx.xxx; however, except as expressly stated herein, the information located on or accessible from, our website is not, and should not be deemed to be, part of this prospectus, any accompanying prospectus supplement or any free writing prospectus or telephoning us at incorporated by reference into any other filing that we submit to the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS JefferiesSEC.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can them. This allows us to disclose important information to you by referring you to those publicly available filed documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-3855038161) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, 2018 (including the information specifically in Part III incorporated therein by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of StockholdersDefinitive Proxy Statement on Schedule 14A); • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 and Quarterly Report onForm 10-Q, and the amendment thereto on Form 10-Q/A, for the quarter ended June 30, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8January 24, 2019, April 11February 20, 2019, May 1, 2019, June 19February 26, 2019 and July 15May 21, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The the description of our common stock contained in our the Registration Statement on Form onForm 8-A filed on June 22July 20, 20182017, including any amendments amendment or reports report filed for the purpose of updating such description. You may request WHERE YOU CAN FIND ADDITIONAL INFORMATION We make periodic filings and other filings required to be filed by us as a reporting company under Sections 13 and 15(d) of the Exchange Act. The SEC maintains an Internet site at xxx.xxx.xxx that contains the reports, proxy and information statements, and other information that we file with the SEC. We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written or oral request, a copy of these filingsany or all of the information that has been incorporated by reference into this prospectus but not delivered with this prospectus, excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. You may obtain copies of this prospectus and the documents incorporated by reference without charge by writing to our investor relations team at no cost0000 Xxxxx Xxxxx Xxxx, Xxxxxxxxx, Xxxxxxxxx 00000, by writing or telephoning us telephone at the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000000)-000-0000 20 or on our website at xxx.xxxxxx.xxx. Information contained on our website is not incorporated into this prospectus and you should not consider information contained on our website to be part of this prospectus. Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT Jefferies

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC Securities and Exchange Commission allows us to “incorporate by reference much of reference” the information we and BioMed file with the SECSecurities and Exchange Commission, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporated by reference is an important part of this Offer to Purchase. The incorporated documents contain significant information about us, our business and our finances. We incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings the following documents BioMed filed with the SEC, this prospectus is continually updated Securities and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completedCommission: • BioMed’s Annual Report on Form 10-K for the fiscal year ended December 31, 20182008, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • BioMed’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; 2009, • BioMed’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, • BioMed’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, • BioMed’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 2, 2009, • BioMed’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2009, • BioMed’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2009, • BioMed’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 18, 2009, • BioMed’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2009, and • BioMed’s Current Reports on Form 8-K filed with the Securities and Exchange Commission on January 3September 4, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports 2009. To the extent that any information contained in any current report on Form 8-K/A , or any exhibit thereto, was furnished to, rather than filed with with, the SEC on June 19Securities and Exchange Commission, 2019 and June 19, 2019, respectively; and • The description of our common stock contained such information or exhibit is specifically not incorporated by reference in our Registration Statement on Form 8-A filed on June 22, 2018this Offer to Purchase. We will provide without charge to each person, including any amendments beneficial owner, to whom an Offer to Purchase is delivered, on written or reports filed oral request of that person, a copy of any or all of the documents we are incorporating by reference into this Offer to Purchase, other than exhibits to those documents unless those exhibits are specifically incorporated by reference into those documents. A written request should be addressed to BioMed Realty Trust, Inc., 00000 Xxxxxxxx Xxxxxx Drive, San Diego, California 92128, Attention: Secretary. The Letter of Transmittal, the Notes, and any other required documents should be sent or delivered by each Holder or such Xxxxxx’s broker, dealer, commercial bank, trust company or other nominee to the Depositary at its address set forth below. To confirm delivery of the Notes, Holders are directed to contact the Depositary. Any questions or requests for assistance may be directed to the purpose Information Agent or the Dealer Manager at the respective telephone numbers and addresses set forth below. Requests for additional copies of updating such descriptionthe Offer to Purchase, the Letter of Transmittal or related documents may be directed to the Information Agent at its telephone numbers or address set forth below. You may request a copy of these filingsalso contact your broker, at no costdealer, by writing commercial bank, trust company or telephoning us at other nominee for assistance concerning the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS JefferiesOffer. The Depositary and Information Agent for the Offer is:

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to "incorporate by reference much of reference" the information we file with the SEC, which them. This means that we can disclose important information to you in this prospectus by referring you to those publicly available documents. These incorporated documents contain important business and financial information about us that is not included in or delivered with this prospectus. The information that we incorporate incorporated by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings , and later information filed with the SEC, SEC will update and supersede this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectusinformation. This means that you must look at all of the SEC filings that we We incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and as well as any future filings we make made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between from the date of the initial registration statement and prior to the effectiveness of this registration statement, and any filings made after the registration statement and following the effectiveness date of the registration statement this prospectus until the offering we sell all of the securities under this prospectus, except that we do not incorporate any document or portion of a document that is "furnished" to the registration statement is terminated or completedSEC, but not deemed "filed." The following documents filed with the SEC are incorporated by reference in this prospectus: • our Annual Report on Form 10-K for the fiscal year ended December 31January 2, 20182016 (including any portions of our Definitive Proxy Statement on Schedule 14A filed on May 2, including the information specifically 2016 that are incorporated by reference into the such Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of StockholdersK); • our Quarterly Report Reports on Form 10-Q for the fiscal quarter quarters ended March 31April 2, 20192016 and July 2, 2016; • our Current Reports on Form 8-K filed on January 313, 20192016, April 8, 2019, April 11, 2019, May February 1, 20192016, February 10, 2016, June 199, 2019 2016 and July 15August 2, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively2016; and • The the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on June 22November 27, 20182006, including any amendments or reports filed for the purpose of updating such description. You may We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, on written or oral request of that person, a copy of these filingsany or all of the documents we are incorporating by reference into this prospectus, at no cost, other than exhibits to those documents unless such exhibits are specifically incorporated by writing or telephoning us at the following address or telephone numberreference into those documents. Such written requests should be addressed to: Translate BioNetlist, Inc. Attention: Xxxx Xxxxxxx000 Xxxxxxxxxx Xxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (Xxxxx 000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS Jefferies

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference into this prospectus much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in into this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-3855038134) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 20182021, including the information specifically incorporated by reference into the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 from our definitive proxy statement for the 2019 2022 Annual Meeting of Stockholders; ​ • Quarterly Report Reports on Form 10-Q for the fiscal quarter quarters ended March 31, 20192022, June 30, 2022 and September 30, 2022 (and with respect to the Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2022 and September 30, 2022, the additional disclosures relating to the Company’s ability to continue as a going concern in Note 2 to the Consolidated Financial Statements contained in such reports); ​ • Current Reports on Form 8-K filed on January February 10, 2022 (with respect to Item 8.01 and the portions of Item 9.01 described therein only), February 15, 2022, March 7, 2022, March 23, 2022, May 5, 2022, May 10, 2022 (with respect to Item 8.01 and the portions of Item 9.01 described therein only), June 14, 2022, August 8, 2022 (with respect to Item 1.01 and the portions of Item 9.01 described therein only), September 6, 2022, September 7, 2022, September 26, 2022, October 3, 20192022 and November 7, April 82022 (with respect to Item 1.01, 2019, April 11, 2019, May 1, 2019, June 19, 2019 Item 5.02 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectivelyportions of Item 9.01 described therein only); and ​ • The description of our common stock registered securities contained in our Registration Statement on Form 8-A filed on June 2226, 20182017, as amended by the descriptions of our registered securities contained in Exhibit 4.2 to our Annual Report on Form 10-K for the year ended December 31, 2021 and including any other amendments or reports filed for the purpose of updating such descriptiondescriptions. You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS Jefferies​

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference much of the information we file with the SECit, which means that we can disclose important information to you by referring you to those publicly available documents. The information another document that we incorporate have filed separately with the SEC. You should read the information incorporated by reference in this prospectus because it is considered to be an important part of this prospectus. Because we are incorporating We incorporate by reference future filings the following information or documents that we have filed with the SEC, this prospectus is continually updated and those future filings may modify or supersede some excluding any portions of any Current Report on Form 8-K that are not deemed “filed” pursuant to the information included or incorporated in this prospectus. This means that you must look at all General Instructions of Form 8-K: ● Our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC filings that we incorporate by reference to determine if on March 29, 2019 and our Form 10-K/A for the year ended December 31, 2018, filed with the SEC on April 29, 2019; ● Our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2019, filed with the SEC on May 13, 2019, for the quarter ended June 30, 2019 filed with the SEC on August 14, 2019 and for the quarter ended September 30, 2019 filed with the SEC on November 14, 2019; ● Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on May 16, 2019; ● Our Current Reports on Form 8-K, filed February 22, 2019, March 15, 2019, March 20, 2019, March 21, 2019, March 25, 2019, June 21, 2019, September 6, 2019, September 23, 2019, September 25, 2019, September 30, 2019, October 22, 2019, December 2, 2019 and December 4, 2019; and ● The description of our common stock set forth in our registration statement on Form 8-A12B, filed April 8, 2013, including any amendments or reports filed for purposes of updating such description. Any information in any of the statements foregoing documents will automatically be deemed to be modified or superseded to the extent that information in this prospectus or in any a later filed document previously that is incorporated or deemed to be incorporated herein by reference have been modified modifies or supersededreplaces such information. This prospectus incorporates We also incorporate by reference the documents listed below (File No. 001-38550) and any future filings we make (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) made with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each caseAct, other than including those documents or the portions of those documents not deemed to be filed) between made after the date of filing of the initial registration statement and the prior to effectiveness of the registration statement and following statement, until we file a post-effective amendment that indicates the effectiveness termination of the registration statement until the offering of the securities under made by this prospectus. Information in such future filings updates and supplements the registration statement information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is terminated incorporated or completed: • Annual Report on Form 10-K for deemed to be incorporated herein by reference to the fiscal year ended December 31, 2018extent that statements in the later filed document modify or replace such earlier statements. We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the information documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018, including any amendments or reports filed for the purpose of updating such descriptiondocuments. You may request a copy of these filings, filings at no cost, by writing to or telephoning us at the following address or telephone numberaddress: Translate BioOragenics, Inc. Inc., 0000 Xxxxxxxxxx Xxxxxxxxx, Xxxxx 000, Xxxxx, Xxxxxxx 00000, Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Corporate Secretary. Up to $50,000,000 20,000,000 Shares of Common Stock PROSPECTUS JefferiesSUPPLEMENT February 1, 2021

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to "incorporate by reference much of reference" into this prospectus supplement and the accompanying base prospectus certain information we file with the SEC, which it. This means that we can disclose important information to you in this prospectus supplement by referring you to those publicly available documents. These incorporated documents contain important business and financial information about us that is not included in or delivered with this prospectus supplement or the accompanying base prospectus. The information that we incorporate incorporated by reference in this prospectus is considered to be part of this prospectus supplement and the accompanying base prospectus. Because we are incorporating by reference future filings , and later information filed with the SEC, this prospectus is continually updated SEC will automatically update and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements contained in this prospectus or in any document previously incorporated by reference have been modified or supersededsupplement and the accompanying base prospectus. This prospectus incorporates We incorporate by reference the documents listed below (File No. 001-38550) and as well as any future filings we make made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each caseAct, other than those documents or the portions of those documents not deemed to be filed) between from the date of this prospectus supplement to the initial registration statement and the effectiveness completion of all offerings of the registration statement and particular securities offered by this prospectus supplement, except that we do not incorporate any document or portion of a document that is "furnished" to the SEC, but not deemed "filed." The following documents filed with the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completedSEC are incorporated by reference in this prospectus: • our Annual Report on Form 10-K for the fiscal year ended December 31, 20182016, filed with the SEC on March 31, 2017, including the information specifically incorporated by reference into the such Annual Report on Form 10-K from our definitive proxy statement on Schedule 14A for the 2019 our Annual Meeting of StockholdersStockholders held on May 31, 2017 and filed with the SEC on May 1, 2017; • our Quarterly Report Reports on Form 10-Q for the fiscal quarter ended March 31April 1, 20192017, filed with the SEC on May 16, 2017, the fiscal quarter ended July 1, 2017, filed with the SEC on August 15, 2017, and the fiscal quarter ended September 30, 2017, filed with the SEC on November 14, 2017; • our Current Reports on Form 8-K filed on January 3March 29, 20192017, April 814, 20192017, April 1117, 20192017, May 5, 2017, May 9, 2017, June 1, 20192017, June 19August 17, 2019 2017 and July 15September 29, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively2017; and • The the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on June 22November 27, 20182006, including any amendments or reports filed for the purpose of updating such description. You may We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, on written or oral request of that person, a copy of these filingsany or all of the documents we are incorporating by reference into this prospectus supplement or the accompanying base prospectus, at no cost, other than exhibits to those documents unless such exhibits are specifically incorporated by writing or telephoning us at the following address or telephone numberreference into those documents. Such written requests should be addressed to: Translate BioNetlist, Inc. 000 Xxxxxxxxxx Xxxxx, Xxxxx 000 Irvine, California 92618 Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 Investor Relations You may direct telephone requests to our Investor Relations Department at (000) 000-0000 20 Up 0000. PROSPECTUS NETLIST, INC. $40,000,000 COMMON STOCK PREFERRED STOCK WARRANTS UNITS We may offer and sell from time to time the above securities in one or more classes, in one or more transactions, separately or together in any combination and as separate series, and in amounts, at prices and on terms that we will determine at the times of the offerings. We may also offer any of these securities that may be issuable upon the conversion, exercise or exchange of preferred stock or warrants. The aggregate initial offering price of the securities that we may offer through this prospectus will be up to $50,000,000 Common Stock 40,000,000. We will provide specific terms of any offering in supplements to this prospectus, which we will deliver together with the prospectus at the time of sale. The supplements may add, update or change information contained in this prospectus. You should read this prospectus and any prospectus supplement carefully before you invest. This prospectus may not be used to offer and sell securities unless accompanied by a prospectus supplement. We may offer the securities independently or together in any combination for sale directly to purchasers, through one or more underwriters, dealers or agents, or through underwriting syndicates managed or co-managed by one or more underwriters, to be designated at a future date, on a continuous or delayed basis. Our common stock is listed on the NASDAQ Capital Market under the symbol "NLST." On August 17, 2016, the last reported sale price of our common stock was $1.60 per share. Investing in our securities involves risks. Risks associated with an investment in our securities will be described in the applicable prospectus supplement and certain of our filings with the Securities and Exchange Commission, as described under the caption "Risk Factors" on page 1 of this prospectus. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS JefferiesIS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this prospectus is September 2, 2016 TABLE OF CONTENTS Page ABOUT NETLIST, INC. 1 RISK FACTORS 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 1 USE OF PROCEEDS 2 SECURITIES WE MAY OFFER 2 DESCRIPTION OF CAPITAL STOCK 3 DESCRIPTION OF WARRANTS 5 DESCRIPTION OF UNITS 6 PLAN OF DISTRIBUTION 7 LEGAL MATTERS 8 EXPERTS 9 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 9 WHERE YOU CAN FIND MORE INFORMATION 9 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, using a "shelf" registration process. Under this shelf registration process, we may, from time to time, sell the securities or combinations of the securities described in this prospectus in one or more offerings in amounts that we will determine from time to time. For further information about our business and the securities, you should refer to the registration statement containing this prospectus and its exhibits. The exhibits to our registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you should review the full text of these documents. We have filed and plan to continue to file other documents with the SEC that contain information about us and our business. Also, we will file legal documents that control the terms of the securities offered by this prospectus as exhibits to the reports we file by the SEC. The registration statement and other reports can be obtained from the SEC as indicated under the heading "Where You Can Find More Information." This prospectus provides you with a general description of the securities that we may offer. Each time we offer securities pursuant to this prospectus, we will provide a prospectus supplement and/or other offering material that will contain specific information about the terms of that offering. When we refer to a "prospectus supplement," we are also referring to any free writing prospectus or other offering material authorized by us. The prospectus supplement may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you should rely on the information in the prospectus supplement or incorporated information having a later date. You should read this prospectus and any prospectus supplement together with additional information described under the headings "Incorporation of Certain Documents by Reference" and "Where You Can Find More Information." You should rely only on the information provided in this prospectus, in any prospectus supplement, or any other offering material that we authorize, including the information incorporated by reference. We have not authorized anyone to provide you with different information. You should not assume that the information in this prospectus, any supplement to this prospectus, or any other offering material that we authorize, is accurate at any date other than the date indicated on the cover page of these documents or the date of the statement contained in any incorporated documents, respectively. This prospectus is not an offer to sell or a solicitation of an offer to buy any securities other than the securities referred to in the prospectus supplement. This prospectus is not an offer to sell or a solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should not interpret the delivery of this prospectus, or any sale of securities, as an indication that there has been no change in our affairs since the date of this prospectus. You should also be aware that information in this prospectus may change after this date. The information contained in this prospectus or a prospectus supplement or amendment, or incorporated herein or therein by reference, is accurate only as of the date of this prospectus or prospectus supplement or amendment, as applicable, regardless of the time of delivery of this prospectus or prospectus supplement or amendment, as applicable, or of any sale of the shares. Unless the context otherwise requires, in this prospectus "Netlist," "we," "us," and "our" refer to Netlist, Inc. and its consolidated subsidiaries.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference much of the into this Prospectus Supplement No. 2 certain information we file with the SECit, which means that we can disclose important information to you by referring you to those publicly available documentsdocuments we have filed with the SEC. The information that we incorporate by reference in into this prospectus Prospectus Supplement No. 2 is considered legally deemed to be a part of this prospectusProspectus Supplement No. Because we are incorporating 2 except for any information superseded by reference future filings with the SECother information contained in, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File into, this Prospectus Supplement No. 001-38550) and any future 2. Our file number for filings we make with the SEC under the Exchange Act is 001-33937 . Any statement contained in this Prospectus Supplement No. 2 or in a document incorporated or deemed to be incorporated by reference in this Prospectus Supplement No. 2 is deemed to be modified or superseded to the extent that a statement contained in this Prospectus Supplement No. 2, or in any other document we subsequently file with the SEC, modifies or supersedes that statement. If any statement is modified or superseded, it does not constitute a part of this Prospectus Supplement No. 2 and the accompanying prospectus, except as modified or superseded. Information that is "furnished to" the SEC shall not be deemed "filed with" the SEC and shall not be deemed incorporated by reference into this Prospectus Supplement No. 2 or the accompanying prospectus. This Prospectus Supplement No. 2 incorporates by reference the following reports and statements filed by us with the SEC: · Current Report on Form 8-K, filed on November 10, 2015; · Current Report on Form 8-K, filed on October 8, 2015; · Current Report on Form 8-K/A, filed on September 21, 2015; · Quarterly Report on Form 10-Q, filed on August 14, 2015; · Current Report on Form 8-K, filed on July 23, 2015; · Current Report on Form 8-K, filed on July 14, 2015; · Definitive Proxy Statement, filed on June 1, 2015; · Preliminary Proxy Statement, filed on May 21, 2015; · Quarterly Report on Form 10-Q, filed on May 14, 2015; · Quarterly Report on Form 10-Q, filed on February 12, 2015; · Annual Report on Form 10-K for the fiscal year ended September 30, 2014, filed on December 29, 2014, as amended on January 28, 2015; and · The description of our Common Stock set forth in our Registration Statement on Form 8-A (Registration No. 33937) filed with the SEC on January 31, 2008, including any amendments thereto or reports filed for the purpose of updating such description. We also incorporate by reference all documents we file (other than documents or portions of documents deemed to be furnished pursuant to the Exchange Act) under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and after the effectiveness of the registration statement of which this Prospectus Supplement No. 2 forms a part and following before the effectiveness filing of a post-effective amendment that indicates that the securities offered by this Prospectus Supplement No. 2 have been sold or that deregisters the securities covered by this Prospectus Supplement No. 2 then remaining unsold. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related Prospectus Supplement No. 2 to the extent that a statement in any other subsequently filed document which is also incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus Supplement No. 2. S-16 Prospectus Dated April 10, 2014 Registration No. 333-193971 LIVEDEAL, INC. $50,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants, or units having a maximum aggregate offering price of $50,000,000. When we decide to sell a particular class or series of securities, we will provide specific terms of the offered securities in a prospectus supplement. The prospectus supplement may also add, update or change information contained in or incorporated by reference into this prospectus. However, no prospectus supplement shall offer a security that is not registered and described in this prospectus at the time of its effectiveness. You should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated by reference into this prospectus, carefully before you invest. This prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered securities. Our common stock is traded on The NASDAQ Capital Market under the symbol “LIVE.” Each prospectus supplement will contain information, where applicable, as to our listing on The NASDAQ Capital Market or any other securities exchange of the securities covered by the prospectus supplement. These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters or through a combination of these methods. See “Plan of Distribution” in this prospectus. We may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The net proceeds we expect to receive from any such sale will also be included in a prospectus supplement. Investing in our securities involves various risks. See “Risk Factors” on page 5 for more Information on these risks. Additional risks, if any, will be described in the prospectus supplement related to a potential offering under the heading “Risk Factors”. You should review that section of the related prospectus supplement for a discussion of matters that investors in such securities should consider. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus or any accompanying prospectus supplement. Any representation to the contrary is a criminal offense. The date of this Prospectus is April 10, 2014 TABLE OF CONTENTS Page No. About This Prospectus 1 Prospectus Summary 1 The Offering 2 Our Company 2 Risk Factors 5 Use Of Proceeds 6 Ratio of Earnings to Fixed Charges 6 Descriptions Of The Securities We May Offer 7 Capital Stock 7 Warrants 9 Debt Securities 11 Units 17 Plan Of Distribution 18 Legal Matters 19 Experts 20 Where You Can Find More Information About Us 20 Incorporation Of Certain Documents By Reference 20 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this shelf registration process, we may offer from time to time securities having a maximum aggregate offering price of $50,000,000. Each time we offer securities, we will prepare and file with the SEC a prospectus supplement that describes the specific amounts, prices and terms of the securities we offer. The prospectus supplement also may add, update or change information contained in this prospectus or the documents incorporated herein by reference. You should read carefully both this prospectus and any prospectus supplement together with additional information described below under the caption “Where You Can Find More Information.” This prospectus does not contain all the information provided in the registration statement until we filed with the offering SEC. For further information about us or our securities offered hereby, you should refer to that registration statement, which you can obtain from the SEC as described below under “Where You Can Find More Information.” You should rely only on the information contained or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any prospectus supplement, as well as information we have previously filed with the SEC and incorporated by reference, is accurate as of the date of those documents only. Our business, financial condition, results of operations and prospects may have changed since those dates. We may sell securities through underwriters or dealers, through agents, directly to purchasers or through any combination of these methods. We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase of securities. The prospectus supplement, which we will prepare and file with the SEC each time we offer securities, will set forth the names of any underwriters, agents or others involved in the sale of securities, and any applicable fee, commission or discount arrangements with them. See “Plan of Distribution.” Unless otherwise mentioned or unless the context requires otherwise, when used in this prospectus, the terms “LiveDeal”, “Company”, “we”, “us”, and “our” refer to LiveDeal, Inc. and its wholly-owned subsidiaries. PROSPECTUS SUMMARY The following summary, because it is a summary, may not contain all the information that may be important to you. This prospectus incorporates important business and financial information about the Company that is not included in, or delivered with, this prospectus. Before making an investment, you should read the entire prospectus and any amendment carefully. You should also carefully read the risks of investing discussed under “Risk Factors” and the registration statement is terminated or completed: • financial statements included in our other filings with the SEC, including in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A which we filed with the SEC on June 19January 10, 2019 2014, and June 19subsequently amended on January 31, 20192014. This information is incorporated by reference into this prospectus, respectively; and • The description you can obtain it from the SEC as described below under the headings “Where You Can Find Additional Information About Us” and “Incorporation of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018Certain Documents by Reference.” We will provide to each person, including any amendments beneficial owner, to whom a prospectus is delivered, a copy of any or reports filed for all of the purpose of updating such descriptioninformation that has been incorporated by reference in the prospectus but not delivered with the prospectus. You may request a copy of these filings, excluding the exhibits to such filings which we have not specifically incorporated by reference in such filings, at no cost, by writing or telephoning us at the following address or telephone numberaddress: Translate BioLiveDeal, Inc. AttentionInc., 000 X. Xxxx Xxxxxxx Xxxx, Xxxxx 000, Xxx Xxxxx, XX 00000 Attn: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS JefferiesSecretary. 1

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC Commission allows us to “incorporate by reference much of reference” the information we file with the SECCommission, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be an important part of this prospectus. Because , and certain information that we are incorporating by reference future filings will later file with the SEC, Commission will automatically update and supersede this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectusinformation. This means that you must look at all of the SEC filings that we We incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and as well as any future filings we make with the SEC under Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each caseexcluding, other than those documents unless otherwise provided therein or the portions of those herein, documents not deemed “filed” with the Commission and information furnished pursuant to be filedItem 2.02 and Item 7.01 on any Current Report on Form 8-K or certain exhibits furnished pursuant to Item 9.01 of Form 8-K) between after the date of the initial registration statement and prior to the effectiveness of this registration statement, and any filings made after the registration statement and following the effectiveness date of the registration statement this prospectus until the offering we sell all of the securities under this prospectus. The following documents filed with the registration statement is terminated or completedCommission are incorporated by reference in this prospectus: • our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • our Current Reports on Form 8-K filed with the Commission on January 34, 2019, April 8January 10, 2019, April 11, 2019, May 1, 2019, June 19February 5, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19March 18, 2019 (other than Items 2.02 and June 19, 2019, respectively9.01); and • The the description of our common stock contained included in our Registration Statement registration statement on Form 8-A A12B (File No. 001-33357) filed with the Commission on June 22March 9, 20182007, including any amendments amendment or reports filed for the purpose of updating such description. You Copies of these filings are available at no cost on our website, xxx.xxxxxxxx.xxx. In addition, you may request a copy of these filings, filings and any amendments thereto at no cost, by writing or telephoning us us. Those copies will not include exhibits to those documents unless the exhibits are specifically incorporated by reference in the documents or unless you specifically request them. You may also request copies of any exhibits to the registration statement at the following address or telephone numberno cost. Please direct your request to: Translate BioXxxxx Xxxxxx 0 Xxxxxx Xxxxxx, Inc. Attention: Xxxx XxxxxxxScience Park P.O. Box 455 Carmiel, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) Israel 20100 +000-0-000-0000 20 Up You should rely only on the information in this prospectus, any prospectus supplement, any applicable free writing prospectus and the documents that are incorporated by reference. We have not authorized anyone else to $50,000,000 Common Stock PROSPECTUS Jefferiesprovide you with different information. We are not offering these securities in any state where the offering is prohibited by law. You should not assume that the information in this prospectus, any prospectus supplement, any applicable free writing prospectus or any incorporated document is accurate as of any date other than the date of the document.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. This prospectus is part of a registration statement that we have filed with the SEC. The SEC allows us to “incorporate by reference much of reference” the information that we file with the SEC, it which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate incorporated by reference in this prospectus is considered to be comprise a part of this prospectusprospectus from the date we file that document. Because we are incorporating Any reports filed by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings we make us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between after the date of this prospectus and before the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until date that the offering of the securities under the registration statement by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained in this prospectus or completed: incorporated by reference in this prospectus. We previously filed the following documents with the SEC, and such filings are incorporated by reference into this prospectus. • Annual Report on Form 10-K for the fiscal year ended December 31December31, 2018, filed February 13, 2019 (including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement portions of ourDefinitive Proxy Statement for the 2019 Annual Meeting of StockholdersStockholders incorporated therein by reference); • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019, filed April 30, 2019; • Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed July 30, 2019; • Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2019, filed October 30, 2019; • Current Reports on Form 8-K K, filed on January February 15, 2019, May 3, 2019, April 8July 9, 2019, April 11September 27, 2019, May 1October 28, 2019, June 19, 2019 and July 15November 29, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19December 3, 2019, respectively; and • The description of our common stock contained in our Registration ourRegistration Statement on Form 8-A filed August 12, 2003, as updated through subsequently filed reports; • The description of our Series D Preferred Stock contained in ourRegistration Statement on June 22Form 8-A, 2018filed May 25, 2016, as updated through subsequently filed reports; and • The description of our Series E Preferred Stock contained in ourRegistration Statement on Form 8-A, filed October 1, 2019, as updated through subsequently filed reports. We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, from the filing of this prospectus until all of the securities offered by this prospectus have been sold or we otherwise terminate the offering of these securities, including all filings made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement; provided, however, that information “furnished” under Item 2.02 or Item 7.01 of Form 8-K or other information “furnished” to the SEC which is not deemed filed is not incorporated by reference in this prospectus and any amendments or reports accompanying prospectus supplement. Information that we subsequently file with the SEC will automatically update and may supersede information in this prospectus, any accompanying prospectus supplement and information previously filed for with the purpose of updating such descriptionSEC. You may request a copy of these filingsfilings (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents) at no cost, cost by writing or telephoning us calling Investor Relations at the following address or and telephone number: Translate BioInvestor Relations Gladstone Commercial Corporation 0000 Xxxxxxxxxx Xxxxx, Inc. Attention: Xxxx XxxxxxxXxxxx 000 McLean, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 Virginia 22102 (000) 000-0000 20 57 Up to $50,000,000 63,000,000 Common Stock PROSPECTUS JefferiesSUPPLEMENT Xxxxx Xxxxxxx Xxxxx & Co. LLC Stifel BTIG Fifth Third Securities

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us the Company to “incorporate by reference much of reference” the information we file it files with the SEC, which means that we the Company can disclose important information to you by referring you to those publicly available documents. The information that we incorporate incorporated by reference is an important part of this Offer to Purchase. Any statement contained in a document which is incorporated by reference in this prospectus Offer to Purchase is considered automatically updated and superseded if information contained in this Offer to be part of this prospectus. Because we are incorporating by reference future filings Purchase, or information that the Company later filed with the SEC, modifies or replaces this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectusinformation. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus The Company incorporates by reference the following documents listed below it filed with the SEC: • its Indenture, dated as of April 2, 2007, among the operating partnership, as issuer, the Company, as guarantor, and U.S. Bank National Association, as trustee, including the form of 3.250% Exchangeable Senior Notes due 2012 (File No. 001incorporated by reference to Exhibit 4.1 of Xxxxxx Realty Corporations’ Current Report on Form 8-38550) and any future filings we make K filed with the SEC under Sections 13(aon April 5, 2007), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • its Current Reports on Form 8-K filed on January 28, 2010, February 2, 2010, February 3, 20192010, March 1, 2010, April 820, 2019, April 11, 2019, May 1, 2019, June 19, 2019 2010 and July 15, 2019, respectively, and the first Current Reports Report on Form 8-K/A K filed with on April 14, 2010; • its Annual Report on Form 10-K for the SEC on June 19year ended December 31, 2019 and June 19, 2019, respectively2009; and • its Quarterly Report on Form 10-Q for the quarter ended March 31, 2010. The description Company is not incorporating by reference any documents or portions thereof or exhibits thereto specifically listed above that are deemed “not filed” with the SEC, including its compensation committee reports and performance graph included or incorporated by reference in any Annual Report on Form 10-K or any information or related exhibits furnished pursuant to Items 2.02 or 7.01 of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018K. To receive a free copy of any of the documents incorporated by reference in this Offer to Purchase, including exhibits, if they are specifically incorporated by reference in the documents, call or write Xxxxxx Realty Corporation, 00000 Xxxx Xxxxxxx Xxxxxxxxx, Xxxxx 000, Xxx Xxxxxxx, Xxxxxxxxxx 00000, Attention: Secretary, (000) 000-0000. In order to tender, a holder must mail or deliver, or cause to be mailed or delivered, a properly completed and signed Letter of Transmittal and any amendments other required documents to the depositary at its address set forth below or reports filed tender through DTC’s ATOP by transmitting their acceptance to DTC in accordance with DTC’s ATOP procedures. A holder tendering notes through ATOP does not need to complete the Letter of Transmittal. Table of Contents The depositary for the purpose of updating such description. You may request a copy of these filingsoffer is: U.S. Bank National Association By Hand, at no costOvernight Delivery or Mail (Registered or Certified Mail Recommended): West Side Flats Operations Center 00 Xxxxxxxxxx Xxxxxx St. Xxxx, by writing or telephoning us at the following address or telephone numberMN 55107 Attn.: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 Specialized Finance (Kilroy) By Facsimile Transmission (for eligible institutions only): (000) 000-0000 20 Up Attn: Specialized Finance Fax cover sheets should provide a call back phone number and request a call back, upon receipt. Confirm receipt by calling: (000) 000-0000 Any questions or requests for assistance may be directed to the dealer managers or the information agent at their respective telephone numbers as set forth below. Any requests for additional copies of this Offer to Purchase, the Letter of Transmittal or related documents may be directed to the information agent. A holder may also contact such holder’s broker, dealer, commercial bank, trust company or other nominee for assistance concerning the offer. The information agent for the offer is: Global Bondholder Services Corporation 00 Xxxxxxxx, Xxxxx 000 Xxx Xxxx, Xxx Xxxx 00000 (000) 000-0000 (toll free) (000) 000-0000 (collect) The dealer managers for the offer are: X.X. Xxxxxx 000 Xxxxxxx Xxxxxx Xxx Xxxx, Xxx Xxxx 00000 (000) 000-0000 (toll free) Attention: Syndicate Desk BofA Xxxxxxx Xxxxx 000 Xxxxx Xxxxx Xxxxxx, 17th Floor Charlotte, North Carolina 28255 (000) 000-0000 (toll free) (000) 000-0000 (collect) Attn: Debt Advisory Services Barclays Capital 000 Xxxxxxx Xxxxxx Xxx Xxxx, Xxx Xxxx 00000 (000) 000-0000 (toll free) (000) 000-0000 (collect) Attn: Liability Management Group Table of Contents EXHIBIT B LETTER OF TRANSMITTAL [Attached] Table of Contents LETTER OF TRANSMITTAL XXXXXX REALTY, L.P. Letter of Transmittal to Tender CUSIP Number Issuer Title of Security 00000XXX0 Xxxxxx Realty, L.P. 3.250% Exchangeable Senior Notes due 2012 Pursuant to the Offer to Purchase dated May 17, 2010 (as the same may be amended or supplemented, the “Offer to Purchase”) The offer will expire at 5:00 p.m., New York City time, on Tuesday, June 15, 2010, unless the offer is extended by Xxxxxx Realty, L.P. in its sole discretion (such time, as the same may be extended, the “expiration time”). Holders of notes must validly tender, and not validly withdraw, their notes (as defined below) at or prior to the expiration time to be eligible to receive the purchase price (as defined in the Offer to Purchase). Tenders of notes may be withdrawn at any time prior to the expiration time, but not thereafter. The depositary for the offer is: U.S. Bank National Association By Hand, Overnight Delivery or Mail (Registered or Certified Mail Recommended): By Facsimile Transmission (for eligible institutions only): West Side Flats Operations Center 00 Xxxxxxxxxx Xxxxxx St. Xxxx, MN 55107 Attn.: Specialized Finance (Kilroy) (000) 000-0000 Attn: Specialized Finance Fax cover sheets should provide a call back number and request a call back, upon receipt. Confirm receipt by calling: (000) 000-0000 Delivery of this Letter of Transmittal (as it may be amended or supplemented, this “Letter of Transmittal” and together with the Offer to Purchase, collectively, the “Offer Documents”) to an address other than as set forth above, or transmission of instructions via a facsimile number other than as listed above, will not constitute a valid delivery. The method of delivery of this Letter of Transmittal, any notes and all other required documents to the depositary, including delivery through The Depository Trust Company (“DTC”) and any acceptance or Agent’s Message delivered through DTC’s Automated Tender Offer Program (“ATOP”), is at the election and risk of holders (as defined below). Xxxxxx Realty, L.P., or the operating partnership, is a Delaware limited partnership. Xxxxxx Realty Corporation, or the Company, is a Maryland corporation and the sole general partner of the operating partnership. Unless otherwise expressly stated or the context otherwise requires, in this Offer to Purchase “we,” “us” and “our” refer to the Company, the operating partnership and the Company’s other subsidiaries. We are offering (the “offer”) to purchase for cash any and all of its outstanding 3.250% Exchangeable Senior Notes due 2012 (the “notes”) from the registered holders thereof (the “holders”), upon the terms and subject to the conditions described in the Offer Documents. Holders should carefully review the information set forth in the Offer Documents, including “Certain Significant Consequences” in the Offer to Purchase, before making a decision with respect to the offer. Table of Contents Capitalized terms used herein and not defined herein have the meaning given to them in the Offer to Purchase. This Letter of Transmittal is to be completed by a holder desiring to tender notes pursuant to the offer unless such holder is executing the tender through ATOP. A holder tendering notes through ATOP does not need to complete this Letter of Transmittal. Holders that are tendering notes by book-entry transfer to the depositary’s account at DTC can execute the tender through ATOP. DTC participants that are accepting the offer must transmit their acceptance to DTC, which will verify the acceptance and execute a book-entry delivery to the depositary’s account at DTC. DTC will then send an Agent’s Message to the depositary for its acceptance. Delivery of the Agent’s Message by DTC will satisfy the terms of the offer as to execution and delivery of a Letter of Transmittal by the participant identified in the Agent’s Message. Delivery of this Letter of Transmittal, any notes and other required documents to DTC does not constitute delivery to the depositary. For a description of certain procedures to be followed in order to tender the notes (through ATOP or otherwise), see “The Offer—Procedure for Tendering Notes” in the Offer to Purchase and the instructions to this Letter of Transmittal. Table of Contents TENDER OF NOTES ¨ CHECK HERE IF CERTIFICATES REPRESENTING TENDERED NOTES ARE ENCLOSED HEREWITH. ¨ CHECK HERE IF TENDERED NOTES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER MADE TO THE ACCOUNT MAINTAINED BY THE DEPOSITARY WITH DTC AND COMPLETE THE FOLLOWING: Name of Tendering Institution: Account Number: Transaction Code Number: Date Tendered: List below the notes to which this Letter of Transmittal relates. If the space provided is inadequate, list the principal amounts on a separately executed schedule and affix the schedule to this Letter of Transmittal. Tenders of notes will be accepted only in principal amounts equal to $50,000,000 Common Stock PROSPECTUS Jefferies1,000 or integral multiples thereof. No alternative, conditional or contingent tenders will be accepted. DESCRIPTION OF NOTES TENDERED Name(s) and Address(es) of Registered Holder(s) or Name of DTC Participant and Participant’s DTC Account Number in which Notes are Held (please fill in if blank) Certificate Numbers* Aggregate Principal Amount Represented Aggregate Principal Amount Tendered** * Need not be completed by holders tendering notes by book-entry transfer. ** Unless otherwise specified, it will be assumed that the entire aggregate principal amount represented by the notes described above is being tendered. See Instruction 3. If tendered by a participant in DTC, and if not already printed above, the participant name(s) and address(es) should be printed exactly as such participant’s name appears on a security position listing as the owner of the notes. The offer is not being made to, and tenders will not be accepted from or on behalf of, holders in any jurisdiction in which the making or the acceptance of the offer would not be in compliance with the laws of such jurisdiction. PAYMENT DATE The payment date for a holder that validly tenders and does not validly withdraw its notes prior to the expiration time and whose notes are accepted for purchase by us is expected to occur on Friday, June 18, 2010. Such a holder will receive the purchase price payable for its notes, plus accrued and unpaid interest to, but not including, the payment date. We may, in our sole discretion, extend the expiration time to a date and time later than 5:00 p.m., New York City time, Tuesday, June 15, 2010. Table of Contents NOTE: SIGNATURES MUST BE PROVIDED BELOW. PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY. Ladies and Gentlemen: The undersigned hereby tenders to the operating partnership, upon the terms and subject to the conditions set forth in the Offer to Purchase, receipt of which is hereby acknowledged, and in accordance with this Letter of Transmittal, the principal amount of the notes indicated in the table above entitled “Description of Notes Tendered” under the column heading “Aggregate Principal Amount Tendered” (or, if nothing is indicated therein, with respect to the entire aggregate principal amount represented by the notes described in such table). The undersigned acknowledges and agrees that the tender of notes made hereby may not be withdrawn except to the extent required by law or in accordance with the procedures set forth in the Offer to Purchase. Subject to, and effective upon, the acceptance for purchase of, and payment for, the principal amount of notes tendered with this Letter of Transmittal in accordance with the terms and subject to the conditions of the offer, the undersigned hereby (a) sells, assigns and transfers to, or upon the order of, the operating partnership, all right, title and interest in and to all of the notes tendered hereby, (b) waives any and all other rights with respect to such notes (including, without limitation, any existing or past defaults and their consequences in respect of such notes and the indenture governing such notes) and (c) releases and discharges the operating partnership from any and all claims the undersigned may have now or may have in the future arising out of or related to the notes, including, without limitation, any claims that the undersigned is entitled to participate in any repurchase, redemption or defeasance of the notes. The undersigned hereby irrevocably constitutes and appoints the depositary as the true and lawful agent and attorney-in-fact of the undersigned (with full knowledge that the depositary also acts as the agent of the operating partnership) with respect to such notes, with full powers of substitution and revocation (such power of attorney being deemed to be an irrevocable power coupled with an interest), to: • present such notes and all evidences of transfer and authenticity to, or transfer ownership of such notes on the account books maintained by DTC and the trustee to, or upon the order of, the operating partnership, • present such notes for transfer of ownership on the books of the operating partnership, and • receive all benefits and otherwise exercise all rights of beneficial ownership of such notes, all in accordance with the terms and conditions of the offer as described in this Letter of Transmittal and in the Offer to Purchase. The undersigned acknowledges and agrees that a tender of notes pursuant to any of the procedures described in the Offer to Purchase and in the instructions to this Letter of Transmittal and an acceptance of such notes by the operating partnership will constitute a binding agreement between the undersigned and the operating partnership upon the terms and subject to the conditions of the offer, which agreement shall be governed by, and construed in accordance with, the laws of the State of New York. The undersigned acknowledges, by tendering notes pursuant to any of the procedures described in the Offer to Purchase and in the instructions to this Letter of Transmittal, under certain circumstances set forth in the Offer to Purchase, the operating partnership is not required to accept for purchase any of the notes tendered. The undersigned hereby represents and warrants that (a) the undersigned has read the Offer to Purchase and this Letter of Transmittal and agrees to all of the terms and conditions of the offer, (b) the undersigned has full power and authority to tender, sell, assign and transfer the notes tendered hereby, and (c) when such tendered notes are accepted for purchase and payment by the operating partnership pursuant to the offer, the operating partnership will acquire good title thereto, free and clear of all liens, restrictions, charges and encumbrances and not subject to any adverse claim or right. The undersigned will, upon request, execute and deliver any additional documents deemed by the depositary or by the operating partnership to be necessary or desirable to complete the sale, assignment and transfer of the notes tendered hereby.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and 38134)and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 20182019, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 2020 Annual Meeting of Stockholders; ​ • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 20192020; ​ • Current Reports on Form 8-K filed on January 7, 2020, February 18, 2020, March 19, 2020 and April 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 20192020, respectively, and Current Reports Report on Form 8-K/A filed with the SEC on June 19February 26, 2019 and June 19, 2019, respectively2020; and ​ • The description of our Class A common stock contained in our Registration Statement on Form 8-A filed on June 2226, 20182017, including any amendments or reports filed for the purpose of updating such description. ​ You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Translate BioBlue Apron Holdings, Inc. AttentionAttn: General Counsel 20 Xxxxxxx Xxxxxx Xxx Xxxx, Xxx Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 00000 Telephone: (000) 000-0000 TABLE OF CONTENTS​ CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus and the documents incorporated by reference herein contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus and the information incorporated by reference in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and we do not assume any obligation to update any forward-looking statements except as required by applicable law. Forward-looking statements are subject to a number of risks, uncertainties and assumptions in other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include: • our expectations regarding our expenses and revenue, our ability to maintain and grow adjusted EBITDA and to achieve profitability, the sufficiency of our cash resources, our needs for additional financing, our ability to effectively manage expenses and cash flows, and our ability to remain in compliance with financial and other covenants under our indebtedness; ​ • our ability, including the timing and extent, to obtain additional financing and sufficiently manage costs and to fund investments in our operations in amounts necessary to support the execution of our growth strategy; ​ • our ability, including the timing and extent, to successfully execute our growth strategy, cost-effectively attract new customers and retain existing customers, and to expand our direct-to-consumer product offerings; ​ • our ability to sustain the recent increase in demand resulting from the COVID-19 (coronavirus) pandemic and to retain new customers; ​ • the potential adverse impact of the COVID-19 pandemic on our operations and results, including as a result of the loss of adequate labor, any prolonged closures, or series of temporary closures, of one or more fulfillment centers, supply chain or carrier interruptions or delays, or changes in consumer behaviors, both when stay-at-home and restaurant restriction orders are lifted and/or as a result of the COVID-19 pandemic’s impact on financial markets and economic conditions; ​ • our ability to identify, consummate and realize the anticipated benefits of strategic alternatives and the structure, terms and specific risks and uncertainties associated with any such potential strategic alternatives; ​ • our expectations regarding the benefits and expected costs and charges associated with our plan to close our Arlington, Texas fulfillment center, together with any potential disruption to our workforce and operations associated with such closure and related transfer of production volume to our Linden, New Jersey and Richmond, California fulfillment centers; ​ • our ability to maintain and grow the value of our brand and reputation; ​ • our expectations regarding, and the stability of, our supply chain, including potential shortages or interruptions in the supply or delivery of ingredients, as a result of COVID-19 or otherwise; ​ TABLE OF CONTENTS • our ability to maintain food safety and prevent food-borne illness incidents; ​ • changes in consumer tastes and preferences or in consumer spending; ​ • our ability to effectively compete; ​ • our ability to attract and retain qualified employees and key personnel; ​ • our ability to comply with modified or new laws and regulations applying to our business; ​ • our vulnerability to adverse weather conditions, natural disasters and pandemics; and ​ • our ability to obtain and maintain intellectual property protection. ​ TABLE OF CONTENTS​ BLUE APRON HOLDINGS, INC. Blue Apron creates incredible experiences. Founded in 2012, we are building a consumer lifestyle brand that symbolizes the emotional human connections that are formed through the cooking experiences we create. Our core product is the meal experience we help our customers create. These experiences extend from discovering new recipes, ingredients, and cooking techniques to preparing meals with families and loved ones to sharing photos and stories of culinary triumphs. Central to these experiences are the original recipes we design and send along with fresh, seasonally inspired ingredients directly to our customers. We also sell wine, which can be paired with our meals, and we sell a curated selection of cooking tools, utensils, pantry items, and add-on products for different culinary occasions, which are tested and recommended by our culinary team. Our customers span ages, geographies, income brackets, and levels of culinary expertise. They include recent college graduates, young couples, families, singles, and empty nesters. Our passionate community of home cooks tell us, through emails, phone calls, and social media, how much Blue Apron has changed their lives. Central to our operations, we have developed an integrated ecosystem that employs technology and expertise across many disciplines. Our supply-demand coordination activities — demand planning, recipe creation, recipe merchandising, fulfillment operations, and marketing — drive our end-to-end value chain. Our principal executive offices are located at 20 Up Xxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000, and our telephone number at that address is (000) 000-0000. Our website address is wxx.xxxxxxxxx.xxx. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. TABLE OF CONTENTS​ RISK FACTORS Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described in this prospectus and any accompanying prospectus supplement, including the risk factors set forth in our filings we make with the SEC from time to $50,000,000 Common Stock PROSPECTUS Jefferiestime, that are incorporated by reference herein, including the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report for the quarter ended March 31, 2020 before making an investment decision pursuant to this prospectus and any accompanying prospectus supplement relating to a specific offering. Our business, financial condition and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties not presently known to us or that we currently deem immaterial that may adversely affect us in the future. TABLE OF CONTENTS​ USE OF PROCEEDS We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. TABLE OF CONTENTS​

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows following documents filed by us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate Securities and Exchange Commission are incorporated by reference in this prospectus is considered to be part prospectus: · Quarterly Report on Form 10-Q, filed on February 14, 2014; · Current Report on Form 8-K, filed on January 31, 2014; · Annual Report on Form 10-K for the fiscal year ended September 30, 2013, filed on January 10, 2014, as amended on January 31, 2014; and · The description of this prospectusour Common Stock set forth in our Registration Statement on Form 8-A (Registration No. Because we are incorporating by reference future filings 33937) filed with the SECSEC on January 31, this prospectus is continually updated and those future filings may modify 2008, including any amendments thereto or supersede some reports filed for the purpose of the information included or incorporated in this prospectusupdating such description. This means that you must look at all of the SEC filings that we We also incorporate by reference all documents we file (other than documents or portions of documents deemed to determine if any of be furnished pursuant to the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550Exchange Act) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or a) after the portions of those documents not deemed to be filed) between the initial filing date of the initial registration statement of which this prospectus is a part and before the effectiveness of the registration statement, and (b) after the effectiveness of the registration statement and following before the effectiveness filing of a post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the registration related prospectus supplement to the extent that a statement until the offering in any other subsequently filed document which is also incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the securities under the registration statement is terminated this prospectus. 20 $50,000,000 LIVEDEAL, INC. Common Stock Preferred Stock Debt Securities Warrants Units PROSPECTUS April 10, 2014 We have not authorized any dealer, salesperson or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the other person to give any information specifically or represent anything not contained in or incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018, including any amendments or reports filed for the purpose of updating such descriptionthis prospectus. You may request a copy must not rely on any unauthorized information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not offer to sell any shares in any jurisdiction where it is unlawful. Neither the delivery of these filingsthis prospectus, at no costnor any sale made hereunder, by writing or telephoning us at shall create any implication that the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 information in this prospectus is correct after the date hereof. Up to $50,000,000 9,789,642 Common Stock LIVE VENTURES PROSPECTUS JefferiesSUPPLEMENT CHARDAN CAPITAL MARKETS LLC The date of this Prospectus Supplement No. 2 is December 11, 2015

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to incorporate by reference in this prospectus supplement and the accompanying prospectus much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement and the accompanying prospectus is considered to be part of this prospectus supplement and the accompanying prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus supplement and the accompanying prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus supplement and the accompanying prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement, the accompanying prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates supplement and the accompanying prospectus incorporate by reference the documents listed below (File No. 001-3855038129) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement offered hereby is terminated or completed: . • Our Annual Report on Form 10-K for the year ended December 31, 2021; • The information included in our definitive proxy statement on Schedule 14A for the 2021 Annual Meeting of Stockholders, filed on April 27, 2021, to the extent incorporated by reference into Part III of the Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders2020; • Quarterly Our Current Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC on June 19February 3, 2019 and June 19, 2019, respectively2022; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 2223, 20182017 as the description therein has been updated and superseded by the description of our capital stock contained in Exhibit 4.4 to our Annual Report on Form 10-K for the year ended December 31, 2021, and including any amendments or and reports filed for the purpose of updating such description. You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Translate BioInvestor Relations Xxxxxxx Therapeutics, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 000 Xxxxxxxx Xxxxxx LexingtonXxxxx Cambridge, Massachusetts 02421 02139 (000) 000-0000 20 Up to PROSPECTUS $50,000,000 300,000,000 Common Stock Preferred Stock Warrants Units We may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus, up to an aggregate amount of $300,000,000. We will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. These securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities and their compensation will be described in the applicable prospectus supplement. Our common stock is traded on The Nasdaq Global Select Market under the symbol “MRSN.” On November 8, 2021, the closing price of our common stock was $9.61. Investing in our securities involves risks. See “Risk Factors” on page 3, and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. Prospectus dated November 18, 2021 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS Jefferies1 RISK FACTORS 3 SUMMARY 2 USE OF PROCEEDS 5 FORWARD-LOOKING STATEMENTS 4 DESCRIPTION OF COMMON STOCK 8 PLAN OF DISTRIBUTION 6 DESCRIPTION OF WARRANTS 12 DESCRIPTION OF PREFERRED STOCK 11 WHERE YOU CAN FIND MORE INFORMATION 14 DESCRIPTION OF UNITS 13 LEGAL MATTERS 15 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 15 EXPERTS 15 You should rely only on the information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to give you information different from that contained in this prospectus. We are not making an offer to sell these securities in any jurisdiction where the offer is not permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of when this prospectus is delivered or when any sale of our securities occurs. Our business, financial condition, results of operations and prospects may have changed since that date.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. These documents are available without charge to you upon written or oral request to the applicable company directed to: For ACE Shareholders: ACE Limited 00 Xxxxxxxxxx Xxxxxx Xxxxxxxx, HM08 Bermuda 0-000-000-0000 Attn: Investor Relations Email: xxxxxxxxxxxxxxxxx@xxxxxxxx.xxx For Chubb Shareholders: The SEC allows us to incorporate by reference much Chubb Corporation 00 Xxxxxxxx Xxxx Xxxx Warren, New Jersey 07059 1-908-903-2000 Attn: Investor Relations Email: xxxxxxxxxxxxxxxxx@xxxxx.xxx This joint proxy statement/prospectus does not constitute an issuance prospectus within the meaning of article 652a of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documentsSwiss Code of Obligations. The information that we incorporate required under article 652a of the Swiss Code of Obligations will be contained in a separate Swiss issuance prospectus, which will be available to shareholders and other interested persons free of charge upon written request from ACE Limited, Xxxxxxxxxxx 00, XX-0000 Xxxxxx, Xxxxxxxxxxx, about 10 days before ACE’s capital increase required to implement the merger. In addition, if you have questions about the merger, the ACE extraordinary general meeting or the Chubb special meeting, or if you need to obtain copies of the accompanying joint proxy statement/ prospectus, proxy cards or other documents incorporated by reference in this prospectus joint proxy statement/ prospectus, you may contact the appropriate contact listed below. You will not be charged for any of the documents you request. For ACE Shareholders: X.X. Xxxx & Co., Inc. 00 Xxxx Xxxxxx New York, New York 10005 xxx@xxxxxx.xxx ACE shareholders: 0-000-000-0000 Banks and Brokerage Firms: +0 000-000-0000 For Chubb Shareholders: Xxxxxxxxx Inc. 000 Xxxxxxxxxx Xxxxxxxxx Xxxxxx Xxxx, Xxx Xxxxxx 00000 xxxxx@xxxxxxxxx.xxx All shareholder inquiries: 000-000-0000 To obtain timely delivery of these documents before XXX’s extraordinary general meeting and Xxxxx’x special meeting, you must request the information no later than October 9, 2015. ACE common shares are traded on the NYSE under the symbol “ACE,” and Chubb common stock is considered traded on the NYSE under the symbol “CB.” TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THE MERGER, THE ACE EXTRAORDINARY GENERAL MEETING Page AND THE CHUBB SPECIAL MEETING 1 SUMMARY 9 Information About the Companies 9 The Merger and the Merger Agreement 10 Merger Consideration 10 Xxxxx’x Reasons for the Merger; Recommendation of the Chubb Board 11 ACE’s Reasons for the Merger; Recommendation of the ACE Board 11 Opinion of Xxxxx’x Financial Advisor 12 Opinion of ACE’s Financial Advisor 13 Chubb Special Meeting of Shareholders 13 ACE Extraordinary General Meeting of Shareholders 14 Interests of Chubb Directors and Executive Officers in the Merger 14 Effect of the Merger on Chubb Stock-Based Awards 15 Regulatory Reviews and Approvals 15 Conditions to be part the Merger 16 No Solicitation 17 Termination 17 Litigation Related to the Merger 18 Accounting Treatment 18 Material United States Federal Income Tax Consequences 18 Material Swiss Tax Consequences 18 Comparison of Shareholders’ Rights 19 No Appraisal Rights 19 SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF ACE 20 SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF CHUBB 23 SELECTED UNAUDITED PRO FORMA COMBINED FINANCIAL DATA 25 COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE FINANCIAL DATA 27 COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND INFORMATION 28 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 29 RISK FACTORS 33 CHUBB SPECIAL MEETING OF SHAREHOLDERS 42 ACE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS 48 PROPOSALS TO BE SUBMITTED TO ACE SHAREHOLDERS 57 INFORMATION ABOUT THE COMPANIES 67 THE MERGER 68 Transaction Structure 68 Merger Consideration 68 Background of the Merger 68 Xxxxx’x Reasons for the Merger; Recommendation of the Chubb Board. 72 Opinion of Xxxxx’x Financial Advisor 75 Certain Unaudited Prospective Financial Information for Chubb and ACE 92 ACE’s Reasons for the Merger; Recommendation of the ACE Board 94 Opinion of ACE’s Financial Advisor 97 Financing 106 Management and Board of Directors of ACE After the Merger 106 Interests of Chubb Directors and Executive Officers in the Merger 106 Regulatory Reviews and Approvals 116 Accounting Treatment 117 NYSE Market Listing; Delisting and Deregistration of Chubb Common Stock 118 THE MERGER AGREEMENT 119 Explanatory Note Regarding the Merger Agreement 119 Effects of the Merger 119 Effective Time of the Merger 119 Effect of the Merger on Chubb Stock-Based Awards 120 Representations and Warranties 121 Covenants and Agreements 125 Conditions to the Merger 133 Termination 134 Effect of Termination and Termination Fee 135 Amendments, Extensions and Waivers 135 Fees and Expenses 135 LITIGATION RELATED TO THE MERGER 136 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES 137 MATERIAL SWISS TAX CONSEQUENCES 145 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS 148 NOTES TO UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS 153 COMPARISON OF SHAREHOLDERS’ RIGHTS 165 NO APPRAISAL RIGHTS 182 CERTAIN BENEFICIAL OWNERS OF ACE COMMON SHARES 183 CERTAIN BENEFICIAL OWNERS OF CHUBB COMMON STOCK 187 VALIDITY OF SECURITIES 191 EXPERTS 192 OTHER MATTERS 193 SHAREHOLDER PROPOSALS FOR NEXT ANNUAL MEETING 194 ENFORCEMENT OF CIVIL LIABILITIES UNDER UNITED STATES FEDERAL SECURITIES LAWS 197 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 198 HOUSEHOLDING OF JOINT PROXY STATEMENT/PROSPECTUS 200 Appendix A Agreement and Plan of Merger, dated as of June 30, 2015, by and among ACE Limited, Xxxxxxx Investment Holdings Corporation and The Chubb Corporation A- i Appendix B Text of Proposed Amendments to ACE’s Articles of Association................................................ B-1 Appendix C Opinion of Guggenheim Securities, LLC ......................................................................................... C-1 Appendix D Opinion of Xxxxxx Xxxxxxx & Co. LLC ............................................................................................. D-1 Appendix E ACE Current Directors, Corporate Governance and Director and Executive QUESTIONS AND ANSWERS ABOUT THE MERGER, THE ACE EXTRAORDINARY GENERAL MEETING AND THE CHUBB SPECIAL MEETING The following are answers to certain questions that you may have regarding the merger, the ACE extraordinary general meeting and the Chubb special meeting. We urge you to read carefully the remainder of this prospectus. Because we are incorporating by reference future filings with joint proxy statement/prospectus because the SEC, information in this prospectus is continually updated and those future filings section may modify or supersede some not provide all of the information included or incorporated that might be important to you in this prospectusdetermining how to vote. This means that you must look at all of Additional important information is also contained in the SEC filings that we incorporate by reference to determine if any of appendices to, and the statements in this prospectus or in any document previously documents incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings we make with the SEC under Sections 13(a)into, 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive this joint proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-Kstatement/A filed with the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed on June 22, 2018, including any amendments or reports filed for the purpose of updating such description. You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Translate Bio, Inc. Attention: Xxxx Xxxxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx Lexington, Massachusetts 02421 (000) 000-0000 20 Up to $50,000,000 Common Stock PROSPECTUS Jefferiesprospectus.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC Commission allows us to “incorporate by reference much of reference” the information we file with the SECCommission, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be an important part of this prospectus. Because , and certain information that we are incorporating by reference future filings will later file with the SEC, Commission will automatically update and supersede this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectusinformation. This means that you must look at all of the SEC filings that we We incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and as well as any future filings we make with the SEC under Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each caseexcluding, other than those documents unless otherwise provided therein or the portions of those herein, documents not deemed “filed” with the Commission and information furnished pursuant to be filedItem 2.02 and Item 7.01 on any Current Report on Form 8-K or certain exhibits furnished pursuant to Item 9.01 of Form 8-K) between after the date of the initial registration statement and prior to the effectiveness of this registration statement, and any filings made after the registration statement and following the effectiveness date of the registration statement this prospectus until the offering we sell all of the securities under this prospectus. The following documents filed with the registration statement is terminated or completedCommission are incorporated by reference in this prospectus: • ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from 2021; ● our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019; • Current Reports on Form 8-K filed on January 3, 2019, April 8, 2019, April 11, 2019, May 1, 2019, June 19, 2019 and July 15, 2019, respectively, and Current Reports on Form 8-K/A filed with the SEC Commission on February 24, 2022, March 31, 2022; and April 4, 2022 (other than Items 2.02 and 9.01); ● our Defintive Proxy Statement, filed on April 29, 2022, for our Annual Meeting of Stockholders scheduled to be held on June 1930, 2019 and June 19, 2019, respectively2022; and • The ● the description of our common stock contained included in our Registration Statement registration statement on Form 8-A A12B (File No. 001-33357) filed with the Commission on June 22March 9, 20182007, including any amendments amendment or reports filed for the purpose of updating such description. You Copies of these filings are available at no cost on our website, xxx.xxxxxxxx.xxx. In addition, you may request a copy of these filings, filings and any amendments thereto at no cost, by writing or telephoning us us. Those copies will not include exhibits to those documents unless the exhibits are specifically incorporated by reference in the documents or unless you specifically request them. You may also request copies of any exhibits to the registration statement at the following address or telephone numberno cost. Please direct your request to: Translate BioXxxx Xxxxx Xx. Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. Attention: Xxxx Xxxxxxx0 Xxxxxxxxxx Xxxxx, Chief Legal Officer 00 Xxxxxxxx Xxxxxx LexingtonXxxxx 000 Hackensack, Massachusetts 02421 NJ 07601 (000) 000-0000 20 Up You should rely only on the information in this prospectus, any prospectus supplement, any applicable free writing prospectus and the documents that are incorporated by reference. We have not authorized anyone else to $50,000,000 Common Stock PROSPECTUS Jefferiesprovide you with different information. We are not offering these securities in any state where the offering is prohibited by law. You should not assume that the information in this prospectus, any prospectus supplement, any applicable free writing prospectus or any incorporated document is accurate as of any date other than the date of the document.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE. The SEC allows us to “incorporate by reference much of reference” the information we file with the SEC, which them into this prospectus. This means that we can disclose important information about us and our financial condition to you by referring you to those publicly available documentsanother document filed separately with the SEC instead of having to repeat the information in this prospectus. The information that we incorporate incorporated by reference in this prospectus is considered to be part of this prospectus. Because prospectus and later information that we are incorporating by reference future filings file with the SEC, SEC will automatically update and supersede this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or supersededinformation. This prospectus incorporates by reference the documents listed below (File No. 001-38550) and any future filings we make made with the SEC under Sections 13(a), 13(c), 14 14, or 15(d) of the Exchange Act (in each caseAct, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the prior to effectiveness of the registration statement and following the effectiveness of documents listed below that we have previously filed with the registration statement until the offering of the securities under the registration statement is terminated or completedSEC: • ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, including the information specifically incorporated by reference into the Annual Report on Form 10-K from 2016; ● our definitive proxy statement for the 2019 Annual Meeting of Stockholders; • Quarterly Report Reports on Form 10-Q for the fiscal quarter periods ended March 31, 20192017, June 30, 2017, and September 30, 2017; • ● our Current Reports on Form 8-K filed on January 3February 2, 2019, April 8, 2019, April 11, 2019, May 1, 20192017, June 19, 2019 2017, June 23, 2017 and July 1518, 2019, respectively, and Current Reports on Form 8-K/A filed with 2017. ● the SEC on June 19, 2019 and June 19, 2019, respectively; and • The description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on June 22December 17, 20182014, including any amendments or reports filed for the purpose of updating such description. We also incorporate by reference all documents that we file with the SEC on or after the effective time of this prospectus pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act and prior to the sale of all the securities registered hereunder or the termination of the registration statement. Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC. Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in the applicable prospectus supplement or in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes the statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You may request a copy of these filingsthe filings incorporated herein by reference, including exhibits to such documents that are specifically incorporated by reference, at no cost, by writing or telephoning calling us at the following address or telephone number: Translate BioXxxxx Xxxxx Chief Executive Officer 0000 Xxxxx Xx., Inc. Attention: Xxxx XxxxxxxSuite 2050 Menlo Park, Chief Legal Officer 00 Xxxxxxxx CA 94025 (650) 446-7888 Statements contained in this prospectus as to the contents of any contract or other documents are not necessarily complete, and in each instance you are referred to the copy of the contract or other document filed as an exhibit to the registration statement or incorporated herein, each such statement being qualified in all respects by such reference and the exhibits and schedules thereto. WHERE YOU CAN FIND MORE INFORMATION This prospectus is part of a registration statement on Form S-3 that we filed with the SEC registering the securities that may be offered and sold hereunder. The registration statement, including exhibits thereto, contains additional relevant information about us and these securities that, as permitted by the rules and regulations of the SEC, we have not included in this prospectus. A copy of the registration statement can be obtained at the address set forth below or at the SEC’s website as noted below. You should read the registration statement, including any applicable prospectus supplement, for further information about us and these securities. We file annual reports, quarterly reports, current reports, proxy statements and other information with the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended. You can inspect and obtain a copy of our reports, proxy statements and other information filed with the SEC at the offices of the SEC’s Public Reference Room at 000 X Xxxxxx LexingtonX.X., Massachusetts 02421 (000) 000Xxxxxxxxxx, X.X. 00000, on official business days during the hours of 10 a.m. to 3 p.m. EST. Please call the SEC at 1-0000 20 800- SEC-0330 for further information on the Public Reference Room. The SEC maintains an Internet website at xxxx://xxx.xxx.xxx where you can access copies of most of our SEC filings. We make our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, available free of charge on our corporate website. In addition, our Code of Ethics and Business Conduct and the charters of our Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee are available on our corporate website. The contents of our corporate website are not incorporated into, or otherwise to be regarded as part of, this Registration Statement on Form S-3. Up to $50,000,000 20,000,000 Common Stock PROSPECTUS JefferiesSUPPLEMENT